These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 7620156

  • 21. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
    Mavrommatis AC, Theodoridis T, Economou M, Kotanidou A, El Ali M, Christopoulou-Kokkinou V, Zakynthinos SG.
    Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
    [Abstract] [Full Text] [Related]

  • 22. Regulation of prostaglandin production in intact fetal membranes by interleukin-1 and its receptor antagonist.
    Brown NL, Alvi SA, Elder MG, Bennett PR, Sullivan MH.
    J Endocrinol; 1998 Dec; 159(3):519-26. PubMed ID: 9834469
    [Abstract] [Full Text] [Related]

  • 23. Pharmacology of interleukin-1-induced neutrophil migration.
    Perretti M, Appleton I, Parente L, Flower RJ.
    Agents Actions; 1993 Dec; 38 Spec No():C64-5. PubMed ID: 8391201
    [Abstract] [Full Text] [Related]

  • 24. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia.
    Pajkrt D, van der Poll T, Levi M, Cutler DL, Affrime MB, van den Ende A, ten Cate JW, van Deventer SJ.
    Blood; 1997 Apr 15; 89(8):2701-5. PubMed ID: 9108387
    [Abstract] [Full Text] [Related]

  • 25. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM, Fisher CJ, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H, Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M.
    Crit Care Med; 1997 Jul 15; 25(7):1115-24. PubMed ID: 9233735
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Recombinant activated protein C attenuates endothelial injury and inhibits procoagulant microparticles release in baboon heatstroke.
    Bouchama A, Kunzelmann C, Dehbi M, Kwaasi A, Eldali A, Zobairi F, Freyssinet JM, de Prost D.
    Arterioscler Thromb Vasc Biol; 2008 Jul 15; 28(7):1318-25. PubMed ID: 18451327
    [Abstract] [Full Text] [Related]

  • 28. [The protective effect of interleukin-1 receptor antagonist on postischemic reperfused myocardium and its possible mechanism].
    Li YJ, Ding WH, Gao W, Huo Y, Hong T, Zhu RY, Ma DL.
    Zhonghua Yi Xue Za Zhi; 2004 Apr 02; 84(7):548-53. PubMed ID: 15144587
    [Abstract] [Full Text] [Related]

  • 29. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
    Kuipers B, van der Poll T, Levi M, van Deventer SJ, ten Cate H, Imai Y, Hack CE, ten Cate JW.
    J Immunol; 1994 Mar 01; 152(5):2438-46. PubMed ID: 8133055
    [Abstract] [Full Text] [Related]

  • 30. Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.
    de Boer JP, Creasey AA, Chang A, Abbink JJ, Roem D, Eerenberg AJ, Hack CE, Taylor FB.
    Infect Immun; 1993 Dec 01; 61(12):5035-43. PubMed ID: 7693593
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Studies on blood coagulation-fibrinolysis system regarding kallikrein-kinin system in the utero-placental circulation during normal pregnancy, labor and puerperium.
    Mutoh S, Kobayashi M, Hirata J, Itoh N, Maki M, Komatsu Y, Yoshida A, Sasa H, Kuroda K, Kikuchi Y.
    Agents Actions Suppl; 1992 Dec 01; 38 ( Pt 2)():320-9. PubMed ID: 1462839
    [Abstract] [Full Text] [Related]

  • 33. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
    Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL.
    JAMA; 1994 Jun 15; 271(23):1836-43. PubMed ID: 8196140
    [Abstract] [Full Text] [Related]

  • 34. Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. A randomised, double blind trial.
    Schoergenhofer C, Matzneller P, Mußbacher M, Schmid JA, Jilma-Stohlawetz P, Zeitlinger M, Jilma B.
    Thromb Haemost; 2017 Aug 30; 117(9):1714-1721. PubMed ID: 28796276
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Blocking the interleukin-1 receptor inhibits leukotriene B4 and prostaglandin E2 generation in human monocyte cultures.
    Conti P, Panara MR, Barbacane RC, Placido FC, Bongrazio M, Reale M, Dempsey RA, Fiore S.
    Cell Immunol; 1992 Nov 30; 145(1):199-209. PubMed ID: 1330330
    [Abstract] [Full Text] [Related]

  • 38. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia.
    Stegenga ME, van der Crabben SN, Blümer RM, Levi M, Meijers JC, Serlie MJ, Tanck MW, Sauerwein HP, van der Poll T.
    Blood; 2008 Jul 01; 112(1):82-9. PubMed ID: 18316629
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The imbalance between coagulation and fibrinolysis is related to the severity of the illness and the prognosis in sepsis.
    Park KJ, Kim HJ, Hwang SC, Lee SM, Lee YH, Hahn MH, Kim SK, Lee WY.
    Korean J Intern Med; 1999 Jul 01; 14(2):72-7. PubMed ID: 10461428
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.